Featured Articles

Novo Nordisk has announced the U.S. launch of Ozempic® (semaglutide) tablets, marking a significant expansion of its blockbuster diabetes franchise by introducing an oral version of the…
Read More...

Novartis has secured approval from the European Commission for its novel therapy Rhapsido, marking a significant advancement in the treatment of chronic spontaneous urticaria (CSU). The…
Read More...

Eli Lilly and Company has announced a definitive agreement to acquire Ajax Therapeutics, a move aimed at strengthening its oncology pipeline with a next-generation treatment for blood…
Read More...

AstraZeneca has received approval from the U.S. Food and Drug Administration for a new self-administered version of its lupus treatment, Saphnelo, marking a significant step forward in…
Read More...

MSD, known as Merck & Co., Inc. in the United States, has entered into a major multi-year partnership with Google Cloud aimed at transforming the pharmaceutical giant into a fully…
Read More...

The U.S. Food and Drug Administration has approved IDVYNSO, a new once-daily, single-tablet regimen developed by Merck, for the treatment of adults living with HIV-1. The therapy is…
Read More...

The U.S. Food and Drug Administration has approved an expanded indication for Tzield (teplizumab-mzwv), allowing its use in children as young as one year old to delay the onset of stage…
Read More...

Boehringer Ingelheim has announced a major expansion of its global Computational Innovation network with the launch of a new artificial intelligence (AI) and machine learning (ML)…
Read More...

Boehringer Ingelheim and Zai Lab have announced a new clinical collaboration aimed at advancing a novel dual-targeting strategy for difficult-to-treat cancers. The partnership will…
Read More...

Daiichi Sankyo and Merck & Co. (known as MSD outside the United States and Canada) have announced that the U.S. Food and Drug Administration has accepted and granted Priority Review…
Read More...

Novo Nordisk has announced a strategic partnership with OpenAI aimed at transforming healthcare through advanced artificial intelligence, with a focus on accelerating drug discovery and…
Read More...

Gilead Sciences, Inc. has announced a definitive agreement to acquire Tubulis GmbH, a clinical-stage biotech firm specializing in next-generation antibody-drug conjugates (ADCs). The…
Read More...

Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with additional…
Read More...

Teva Pharmaceutical Industries has announced a series of significant milestones in its biosimilars portfolio, underscoring progress in its broader “Pivot to Growth” strategy and…
Read More...

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, marking a significant step in Biogen’s strategy to…
Read More...

Merck & Co.—known as MSD outside North America—has announced a definitive agreement to acquire Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening…
Read More...

UCB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending an update to the marketing authorization for…
Read More...

Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines, a privately held firm focused on developing T cell engager therapies for autoimmune diseases. The move…
Read More...

Novartis has announced a strategic agreement with Synnovation Therapeutics, LLC to acquire SNV4818, an investigational oral therapy designed to treat hormone receptor-positive,…
Read More...

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), a novel oral therapy for the treatment of moderate-to-severe…
Read More...